Cytoreductive surgery without intra-peritoneal chemotherapy for metachronous colorectal peritoneal metastases.
Humans
Peritoneal Neoplasms
/ secondary
Cytoreduction Surgical Procedures
/ mortality
Male
Female
Colorectal Neoplasms
/ pathology
Middle Aged
Aged
Survival Rate
Prognosis
Follow-Up Studies
Adult
Retrospective Studies
Neoplasm Recurrence, Local
/ pathology
Neoplasms, Second Primary
/ surgery
Hyperthermic Intraperitoneal Chemotherapy
/ methods
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
5-year overall survival
5-year relapse-free survival
Colorectal cancer
Cytoreductive surgery
Metachronous peritoneal metastases
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
31 Jul 2024
31 Jul 2024
Historique:
received:
03
01
2024
accepted:
16
07
2024
medline:
1
8
2024
pubmed:
1
8
2024
entrez:
31
7
2024
Statut:
epublish
Résumé
Cytoreductive surgery and chemotherapy reportedly improve the prognosis of patients with metachronous peritoneal metastases. However, the types of peritoneal metastases indicated for cytoreductive surgery remains unclear. Therefore, we aimed to clarify the category of cases for which cytoreductive surgery would be effective and report the prognosis associated with cytoreductive surgery for metachronous peritoneal metastases. This study included 52 consecutive patients who underwent cytoreductive surgery for metachronous peritoneal metastases caused by colorectal cancer between January 2005 and December 2018 and fulfilled the selection criteria. The median follow-up period was 54.9 months. Relapse-free survival was calculated as the time from cytoreductive surgery of metachronous peritoneal metastases to recurrence. Overall survival was defined as the time from cytoreductive surgery of metachronous peritoneal metastases to death or the end of the follow-up period. The 5-year relapse-free survival rate was 30.0% and the 5-year overall survival rate was 72.3%. None of the patients underwent hyperthermic intraperitoneal chemotherapy. The analysis indicated no potential risk factors for 5-year relapse-free survival. However, for 5-year overall survival, the multivariate analysis revealed that time to diagnosis of metachronous peritoneal metastases of < 2 years after primary surgery (hazard ratio = 4.1, 95% confidence interval = 2.0-8.6, p = 0.0002) and number of metachronous peritoneal metastases ≥ 3 (hazard ratio = 9.8, 95% confidence interval = 2.3-42.3, p = 0.002) as independent factors associated with a poor prognosis. Long intervals of more than 2 years after primary surgery and 2 or less metachronous peritoneal metastases were good selection criteria for cytoreductive surgery for metachronous peritoneal metastases from colorectal cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Cytoreductive surgery and chemotherapy reportedly improve the prognosis of patients with metachronous peritoneal metastases. However, the types of peritoneal metastases indicated for cytoreductive surgery remains unclear. Therefore, we aimed to clarify the category of cases for which cytoreductive surgery would be effective and report the prognosis associated with cytoreductive surgery for metachronous peritoneal metastases.
METHODS
METHODS
This study included 52 consecutive patients who underwent cytoreductive surgery for metachronous peritoneal metastases caused by colorectal cancer between January 2005 and December 2018 and fulfilled the selection criteria. The median follow-up period was 54.9 months. Relapse-free survival was calculated as the time from cytoreductive surgery of metachronous peritoneal metastases to recurrence. Overall survival was defined as the time from cytoreductive surgery of metachronous peritoneal metastases to death or the end of the follow-up period.
RESULTS
RESULTS
The 5-year relapse-free survival rate was 30.0% and the 5-year overall survival rate was 72.3%. None of the patients underwent hyperthermic intraperitoneal chemotherapy. The analysis indicated no potential risk factors for 5-year relapse-free survival. However, for 5-year overall survival, the multivariate analysis revealed that time to diagnosis of metachronous peritoneal metastases of < 2 years after primary surgery (hazard ratio = 4.1, 95% confidence interval = 2.0-8.6, p = 0.0002) and number of metachronous peritoneal metastases ≥ 3 (hazard ratio = 9.8, 95% confidence interval = 2.3-42.3, p = 0.002) as independent factors associated with a poor prognosis.
CONCLUSIONS
CONCLUSIONS
Long intervals of more than 2 years after primary surgery and 2 or less metachronous peritoneal metastases were good selection criteria for cytoreductive surgery for metachronous peritoneal metastases from colorectal cancer.
Identifiants
pubmed: 39085860
doi: 10.1186/s12957-024-03471-w
pii: 10.1186/s12957-024-03471-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
205Informations de copyright
© 2024. The Author(s).
Références
Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7. https://doi.org/10.1200/JCO.2011.37.1039 .
doi: 10.1200/JCO.2011.37.1039
pubmed: 22162570
Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012;13:e362–9. https://doi.org/10.1016/S1470-2045(12)70210-3 .
doi: 10.1016/S1470-2045(12)70210-3
pubmed: 22846841
Kobayashi H, Kotake K, Funahashi K, Hase K, Hirata K, Iiai T, et al. Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis. J Gastroenterol. 2014;49:646–54. https://doi.org/10.1007/s00535-013-0820-3 .
doi: 10.1007/s00535-013-0820-3
pubmed: 23793379
Ozawa H, Kotake K, Kobayashi H, Kobayashi H, Sugihara K. Prognostic factors for peritoneal carcinomatosis originating from colorectal cancer: an analysis of 921 patients from a multi-institutional database. Surg Today. 2014;44:1643–50. https://doi.org/10.1007/s00595-013-0735-x .
doi: 10.1007/s00595-013-0735-x
pubmed: 24077999
Kobayashi H, Enomoto M, Higuchi T, Uetake H, Iida S, Ishikawa T, et al. Validation and clinical use of the Japanese classification of colorectal carcinomatosis: benefit of surgical cytoreduction even without hyperthermic intraperitoneal chemotherapy. Dig Surg. 2010;27:473–80. https://doi.org/10.1159/000320460 .
doi: 10.1159/000320460
pubmed: 21063124
Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99:699–705. https://doi.org/10.1002/bjs.8679 .
doi: 10.1002/bjs.8679
pubmed: 22287157
van Gestel YR, de Hingh IH, van Herk-Sukel MP, van Erning FN, Beerepoot LV, Wijsman JH, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol. 2014;38:448–54. https://doi.org/10.1016/j.canep.2014.04.004 .
doi: 10.1016/j.canep.2014.04.004
pubmed: 24841870
Quere P, Facy O, Manfredi S, Jooste V, Faivre J, Lepage C, et al. Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: a population-based study. Dis Colon Rectum. 2015;58:743–52. https://doi.org/10.1097/DCR.0000000000000412 .
doi: 10.1097/DCR.0000000000000412
pubmed: 26163953
Kumar R, Price TJ, Beeke C, Jain K, Patel G, Padbury R, et al. Colorectal cancer survival: an analysis of patients with metastatic disease synchronous and metachronous with the primary tumor. Clin Colorectal Cancer. 2014;13:87–93. https://doi.org/10.1016/j.clcc.2013.11.008 .
doi: 10.1016/j.clcc.2013.11.008
pubmed: 24373733
Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol. 2007;14:786–94. https://doi.org/10.1245/s10434-006-9215-5 .
doi: 10.1245/s10434-006-9215-5
pubmed: 17103254
Nagata H, Ishihara S, Hata K, Murono K, Kaneko M, Yasuda K, et al. Survival and prognostic factors for metachronous peritoneal metastasis in patients with colon cancer. Ann Surg Oncol. 2017;24:1269–80. https://doi.org/10.1245/s10434-016-5732-z .
doi: 10.1245/s10434-016-5732-z
pubmed: 27995451
Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. UICC International Union Against Cancer, 7th Edition. New York: Wiley; 2009.
van Oudheusden TR, Razenberg LG, van Gestel YR, Creemers GJ, Lemmens VE, de Hingh IH. Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin. Sci Rep. 2015;5:18632. https://doi.org/10.1038/srep18632 .
doi: 10.1038/srep18632
pubmed: 26686250
pmcid: 4685443
Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65–71. https://doi.org/10.1007/s10434-004-1167-z .
doi: 10.1007/s10434-004-1167-z
pubmed: 15827780
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43. https://doi.org/10.1200/JCO.2003.04.187 .
doi: 10.1200/JCO.2003.04.187
pubmed: 14551293
Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92. https://doi.org/10.1200/JCO.2004.10.012 .
doi: 10.1200/JCO.2004.10.012
pubmed: 15310771
Sánchez-Hidalgo, JM, Rodríguez-Ortiz, L, Arjona-Sánchez Á, Rufián-Peña, S, Casado-Adam, Á, Cosano-Álvarez, et al. Colorectal peritoneal metastases: optimal management review. World J. Gastroenterol. 2019, 25, 3484–3502. https://pubmed.ncbi.nlm.nih.gov/31367152/
Bakkers, C, Lurvink RJ, Rijken A, Nienhuijs SW, Kok N.F, Creemers GJ, Verhoef C, et al. Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases: a population-based study. Ann Surg. Oncol. 2021;28:9073–83. https://pubmed.ncbi.nlm.nih.gov/34076807/
Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicenter, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:256–266. https://doi.org/10.1016/S1470-2045(20)30599-4 .
Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P., Crezee J, Aalbers AGJ, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicenter, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4:761–70. https://doi.org/10.1016/S2468-1253(19)30239-0 .
Segelman J, Akre O, Gustafsson UO, Bottai M, Martling A. Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer. Colorectal Dis. 2014;16:359–67. https://doi.org/10.1111/codi.12552 .
doi: 10.1111/codi.12552
pubmed: 24410859
Bushati M, Rovers K, Sommariva A, Sugarbaker P, Morris D, Yonemura Y, et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol (EJSO). 2018;44:1942–8 https://pubmed.ncbi.nlm.nih.gov/34020808 .
doi: 10.1016/j.ejso.2018.07.003
pubmed: 30075978
Abdel-Rahman O. A real-world, population-based study of the outcomes of patients with metastatic colorectal cancer to the peritoneum treated with or without cytoreductive surgery. Int J Colorectal Dis. 2020;35:719–25. https://pubmed.ncbi.nlm.nih.gov/32060606/
Xue L, Hyman NH, Turaga KK, Eng OS. Peritoneal metastases in colorectal cancer: biology and barriers. J Gastrointest Surg. 2020;24:720–727. https://pubmed.ncbi.nlm.nih.gov/31745890/
Bloemendaal AL, Verwaal VJ, van Ruth S, Boot H, Zoetmulder FA. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study. Eur J Surg Oncol. 2005;31:1145–51. https://doi.org/10.1016/j.ejso.2005.06.002 .
doi: 10.1016/j.ejso.2005.06.002
pubmed: 16084051
Klaver YL, Leenders BJ, Creemers GJ, Rutten HJ, Verwaal VJ, Lemmens VE, et al. Addition of biological therapies to palliative chemotherapy prolongs survival in patients with peritoneal carcinomatosis of colorectal origin. Am J Clin Oncol. 2013;36:157–61. https://doi.org/10.1097/COC.0b013e3182438c55 .
doi: 10.1097/COC.0b013e3182438c55
pubmed: 22314003
Ohira G, Miyauchi H, Hayano K, Maruyama M, Imanishi S, Tochigi T, et al. Treatment outcome of resection of disseminated peritoneal metastases from colorectal cancer. In Vivo. 2020;34:1915–20. https://doi.org/10.21873/invivo.11988
Carmignani CP, Ortega-Perez G, Sugarbaker PH. The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer. Eur J Surg Oncol. 2004;30:391–8. https://doi.org/10.1016/j.ejso.2004.01.017 .
doi: 10.1016/j.ejso.2004.01.017
pubmed: 15063892
Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol. 2005;12:900–9. https://doi.org/10.1245/ASO.2005.01.010 .
doi: 10.1245/ASO.2005.01.010
pubmed: 16184442
van Gestel YR, Thomassen I, Lemmens VE, Pruijt JF, van Herk-Sukel MP, Rutten HJ, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol. 2014;40:963–9. https://doi.org/10.1016/j.ejso.2013.10.001 .
doi: 10.1016/j.ejso.2013.10.001
pubmed: 24183168
Sugarbaker PH, Chang D. Peritoneal metastases from colorectal cancer in the absence of lymph node metastases show a high survival rate despite unfavorable prognostic indicators. Eur J Surg Oncol. 2022;48:1619–25. https://doi.org/10.1016/j.ejso.2022.02.001 .
doi: 10.1016/j.ejso.2022.02.001
pubmed: 35177314
Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128:2717–25. https://doi.org/10.1002/ijc.25596 .
doi: 10.1002/ijc.25596
pubmed: 20715167
Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8. https://doi.org/10.1200/JCO.2009.23.9285 .
doi: 10.1200/JCO.2009.23.9285
pubmed: 19917863
Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5. https://doi.org/10.1200/JCO.2008.19.7160 .
doi: 10.1200/JCO.2008.19.7160
pubmed: 19103728
da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203:878–86. https://doi.org/10.1016/j.jamcollsurg.2006.08.024 .
doi: 10.1016/j.jamcollsurg.2006.08.024
pubmed: 17116556
Mendoza-Moreno F, Diez-Alonso M, Matias-Garcia B, Ovejero-Merino E, Gomez-Sanz R, Blazquez-Martin A, et al. Prognostic factors of survival in patients with peritoneal metastasis from colorectal cancer. J Clin Med. 2022;11:4922. https://doi.org/10.3390/jcm11164922 .
doi: 10.3390/jcm11164922
pubmed: 36013160
pmcid: 9410473
Larsen SG, Goscinski MA, Dueland S, Steigen SE, Hofsli E, Torgunrud A, et al. Impact of KRAS, BRAF and microsatellite instability status after cutoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. Br J Cancer. 2022;126:726–35. https://doi.org/10.1038/s41416-021-01620-6 .
doi: 10.1038/s41416-021-01620-6
pubmed: 34887523
Baratti D, Kusamura S, Niger M, Perrone F, Milione M, Cattaneo L, et al. Prognostic impact of primary side and RAS/RAF mutations in a surgical series of colorectal cancer with peritoneal metastases. Ann Surg Oncol. 2020;27:98–106. https://pubmed.ncbi.nlm.nih.gov/32974694/
Sherman SK, Schuitevoerder D, Chan CHF, Turaga KK. Metastatic colorectal cancers with mismatch repair deficiency result in worse survival regardless of peritoneal metastases. Ann Surg Oncol. 2020;27:5074–83. https://pubmed.ncbi.nlm.nih.gov/32583196/
Díez-Alonso, M, Mendoza-Moreno F, Gómez-Sanz R, Matías-García B, Ovejero-Merino E, Molina R, et al. Prognostic value of KRAS gene mutation on survival of patients with peritoneal metastases of colorectal adenocarcinoma. Int J Surg Oncol. 2021;3946875. https://pubmed.ncbi.nlm.nih.gov/34557315/